JPM 2021: Medtronic, Biogen, Edwards LifeSciences, Guardant Health, Illumina
Executive Summary
The annual J.P. Morgan Healthcare Conference includes presentations from many major medtech companies outlining their growth strategies and expectations for 2021. Here are some of the highlights from the first day of the meeting.
You may also be interested in...
Illumina Advances Precision Oncology And Gains Speed In Infectious Disease
Illumina’s moves into infectious disease testing and further into the clinical setting have been accelerated by the pandemic. The genomic sequencing company is also fast expanding its companion diagnostics oncology partnerships.
Guardant Health Launches Liquid Biopsy Test For Detecting Colorectal Cancer Recurrence
Guardant wants to become “one-stop-shop” in the cancer care continuum with the launch of an early-stage colorectal cancer test and planned launch of a tissue-based test.
Edwards Keeps TAVR Going During COVID-19 Surge
Fourth-quarter sales of Edwards Sapien transcatheter aortic valve systems grew 2% year-over-year overall, despite the intense challenges created by COVID-19.